abstract |
The present invention relates to an iRNA (e.g., double-stranded ribonucleic acid (dsRNA)) composition targeting the C5 gene of the complement component, and the use of such iRNA (e.g., dsRNA) composition to suppress C5 performance and to treat the onset and complement component Methods for individuals with C5 related diseases (eg, paroxysmal nocturnal hemeuria). |